Growth Metrics

Esperion Therapeutics (ESPR) Cash & Current Investments (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Cash & Current Investments readings, the most recent being $167.9 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 15.95% to $167.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $167.9 million, a 15.95% increase, with the full-year FY2025 number at $167.9 million, up 15.95% from a year prior.
  • Cash & Current Investments hit $167.9 million in Q4 2025 for Esperion Therapeutics, up from $92.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $259.3 million in Q4 2021 to a low of $82.2 million in Q4 2023.
  • Median Cash & Current Investments over the past 5 years was $164.6 million (2022), compared with a mean of $161.2 million.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 82.63% in 2022 and later plummeted 54.54% in 2025.
  • Esperion Therapeutics' Cash & Current Investments stood at $259.3 million in 2021, then plummeted by 35.66% to $166.9 million in 2022, then crashed by 50.71% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then grew by 15.95% to $167.9 million in 2025.
  • The last three reported values for Cash & Current Investments were $167.9 million (Q4 2025), $92.4 million (Q3 2025), and $86.1 million (Q2 2025) per Business Quant data.